Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ovid Therapeutics Inc.OVID · Entity 5411 | SVP and General Counsel | February 24, 2019 | February 27, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ovid Therapeutics Inc.
Report date February 24, 2019 · Filed February 27, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.89 · Expires 2029-02-23 | Direct | 40,000 |
Reported balance
After 2019-02-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-24 · Grant · Acquired 40,000 · Balance 40,000 F1: 25% of the shares subject to the Stock Option will vest and become exercisable on February 24, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the Stock Option will vest and become exercisable on February 24, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2019 Filed Feb 27, 2019 02:44 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-19-013907 · doc4.xml · derivative · entry 1 Ward Ana · CIK 0001716354 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on February 24, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 22:28 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (right to buy) · Derivative | 11,250 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0001209191-18-048861 · doc4.xml · derivative · entry 1 Ward Ana · CIK 0001716354 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires 2028-08-27 F1 · derivative.exercise_date: The option, representing a right to purchase a total of 11,250 shares becomes exercisable in two equal annual installments beginning on August 27, 2019, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 21:45 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $9.18 | $0.00 |
DisclosureSEC source: 0001209191-18-004913 · doc4.xml · derivative · entry 1 Ward Ana · CIK 0001716354 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-01-18 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on January 19, 2019 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued service through each such date. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 22:23 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option Grant (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $8.38 | $0.00 |
DisclosureSEC source: 0001209191-17-051748 · doc4.xml · derivative · entry 1 Ward Ana · CIK 0001716354 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2027-09-04 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on September 1, 2018 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.